Clinical Trials

JBCRG-11TC TR

Translational research for JBCRG-11TC("Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy.")

Status
No Longer Recruiting

Objectives
Identification of a molecular marker to predict the therapeutic effect and a marker for "Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy."

Subjects
Among the patients who participated in the "Evaluation of the Usefulness of Pre-operative Exemestane (EXE) Therapy for Treatment of Hormone-Sensitive Breast Cancer in Postmenopausal Patients, and EXE + TC Combination Therapy for Nonresponders to EXE Therapy." those who submitted tumor tissue and blood samples for this study.

1)Paraffin block 2)Frozen section 3)Serum 4)Blood sample for CEC

Endpoints
1) Analysis of paraffin embedded samples, before, after and during treatment. 2) Analysis and immunostaining of frozen section, Expression analysis of mRNA. 3) Analysis of blood samples.

Trial Period
2010.Oct~2022.Sep(Entry period:2years, Follow up period :10years from last entry)

Lead Principal Investigator
Masakazu Toi(Kyoto University), Hironobu Sasano(Tohoku University), Takayuki Ueno(Kyorin University)

Target Sample Size
Patients who agreed to enter JBCRG-11TC TR

Regimen

Source of Funding
Japan Breast Cancer Reserch Group

Conference Presentation

Articles and Publications

UMIN-ID
UMIN000004752

jRCT

Memo

COI Disclosure

Previous PageClinical TrialsNext Page